| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/02/2002 | EP1165131A2 Attenuated dengue-1 virus vaccine |
| 01/02/2002 | EP1165130A2 Attenuated dengue-3 virus vaccine |
| 01/02/2002 | EP1165129A1 Attenuated dengue-4 virus vaccine |
| 01/02/2002 | EP1165128A2 Attenuated dengue-2 virus vaccine |
| 01/02/2002 | EP1165127A2 Multivalent dengue virus vaccine |
| 01/02/2002 | EP1165126A1 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 01/02/2002 | EP1165125A2 Antigen-specific induction of peripheral immune tolerance |
| 01/02/2002 | EP1165124A1 Recombinant neospora antigens and their uses |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165109A1 Treatment of autoimmune disease |
| 01/02/2002 | EP1165096A2 Use of cytidine derivatives for the treatment of leukaemia |
| 01/02/2002 | EP1165078A1 Methods of inducing cancer cell death and tumor regression |
| 01/02/2002 | EP1005372B1 Anti-cd40l immunotoxins for the treatment of diseases |
| 01/02/2002 | EP0634408B1 Depsipeptide derivative, production thereof and use thereof |
| 01/02/2002 | CN1329669A Streptococcal C5a peptidase vaccine |
| 01/02/2002 | CN1329508A Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 01/02/2002 | CN1329504A F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy |
| 01/02/2002 | CN1329169A Production of oral vaccine and antibiotic peptide active matter by using transgenic saline algae |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335427 Component of stem bromelain |
| 01/01/2002 | US6335424 ribG |
| 01/01/2002 | US6335199 Gene therapy |
| 01/01/2002 | US6335183 Stress proteins and uses therefor |
| 01/01/2002 | US6335182 Recombinant Haemophilus influenzae adhesin proteins |
| 01/01/2002 | US6335181 Generating polypeptide; for use in the diagnosis, prevention and treatment of bacterial infection |
| 01/01/2002 | US6335180 Nucleic acid sequences encoding capsaicin receptor and uses thereof |
| 01/01/2002 | US6335158 Immunologically active peptide of given amino acid sequence which binds antibodies against retroviruses of the hiv type; diagnostic kits |
| 01/01/2002 | US6335039 Pharmaceutical formulations comprising vegetal material selected from trichilia |
| 01/01/2002 | US6335020 Allergenic peptides from ragweed pollen |
| 01/01/2002 | US6335019 Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen |
| 01/01/2002 | US6335018 Protection against bacterial pathogens(otitis media), induction of antibodies |
| 01/01/2002 | US6335017 Compositions and methods for treating viral infections |
| 01/01/2002 | US6335016 Chicken embryo lethal orphan (CELO) virus |
| 01/01/2002 | CA1341331C Viral vector and recombinant dna coding for one or more structural protein (ha, f and/or np) of a morbillivirus, infected cell culture, resulting proteins, vaccine and antibodies |
| 12/29/2001 | CA2351904A1 Target |
| 12/27/2001 | WO2001098499A1 Antigenic polypeptides |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098464A2 Continuous adherent melanocyte cell line |
| 12/27/2001 | WO2001098460A2 Fusion proteins of mycobacterium tuberculosis |
| 12/27/2001 | WO2001098363A2 Peptides for use in the immunotherapy of renal cell carcinoma |
| 12/27/2001 | WO2001098361A2 Agonist anti-trk-c monoclonal antibodies |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098351A2 G-protein coupled receptors |
| 12/27/2001 | WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | WO2001098335A2 Transgenic algae for delivering antigens to an animal |
| 12/27/2001 | WO2001098334A2 Streptococcus antigens |
| 12/27/2001 | WO2001098333A2 Modification of hepatitis b core antigen |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098277A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 12/27/2001 | WO2001098206A1 Delivery vehicle composition and methods for delivering antigens and other drugs |
| 12/27/2001 | WO2001097859A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | WO2001097858A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 12/27/2001 | WO2001097850A2 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | WO2001097846A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/27/2001 | WO2001097844A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | WO2001097842A1 Curing method for pathologic syndrome and a medicinal preparation |
| 12/27/2001 | WO2001097841A2 Qs-21 and il-12 as an adjuvant combination |
| 12/27/2001 | WO2001097840A1 Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
| 12/27/2001 | WO2001097839A1 Recombinant vaccines against infectious bursal disease virus |
| 12/27/2001 | WO2001097838A2 Adjuvants and processes to induce a specific type of immune response |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097836A1 Compositions and methods for treatment of candidiasis |
| 12/27/2001 | WO2001097827A1 Mhc peptides over-expressed on prostate cancer cells and methods of use |
| 12/27/2001 | WO2001097821A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 12/27/2001 | WO2001097608A2 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods |
| 12/27/2001 | WO2001079511A3 Hemolysin fusion proteins, their production and use |
| 12/27/2001 | WO2001066136A3 Microbial delivery system |
| 12/27/2001 | WO2001062282A3 Adjuvants for vaccines |
| 12/27/2001 | WO2001059088A3 Vector |
| 12/27/2001 | WO2001055353A3 Recombinant attenuation of prrsv |
| 12/27/2001 | WO2001051608A3 Hybrid cells obtainable from antigen presenting cells |
| 12/27/2001 | WO2001051516A3 Fusion proteins for stimulating cytotoxic t-cells |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001047549A3 Conjugate useful as building block for vaccine preparation |
| 12/27/2001 | WO2001045738A3 Use of heat shock proteins to enhance production of chemokines by a cell |
| 12/27/2001 | WO2001044278A3 Antigen preparations |
| 12/27/2001 | WO2001043769A3 Antigen delivery |
| 12/27/2001 | WO2001038490A3 ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| 12/27/2001 | WO2001037863A3 Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen |
| 12/27/2001 | WO2001036453A3 Ny-eso-1 nanopeptide derivatives, and uses thereof |
| 12/27/2001 | WO2001034189A3 Vaccines for mycoplasma bovis and methods of use |
| 12/27/2001 | WO2001031019A3 Neisserial antigenic peptides |
| 12/27/2001 | WO2000064864A9 N-protected amines and their use as prodrugs |
| 12/27/2001 | US20010056124 Such as 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol, in free form or as salt to treat organ or tissue allo- or xeno-transplant rejection |
| 12/27/2001 | US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
| 12/27/2001 | US20010056063 Method of treating or preventing type 1 diabetes by oral administration of insulin |
| 12/27/2001 | US20010055791 Methods for enhancing the production of interferon in cell culture |
| 12/27/2001 | US20010055780 Bacteriophage coupling to enzyme |
| 12/27/2001 | US20010055777 Potentiation of the immune response |
| 12/27/2001 | US20010055758 Reagents and methods useful for detecting diseases of the prostate |
| 12/27/2001 | US20010055751 PSCA: Prostate stem cell antigen and uses thereof |
| 12/27/2001 | US20010055596 Compositions and methods for therapy and diagnosis of colon cancer |
| 12/27/2001 | US20010055593 CD86 (B7) proteins; downmodulating an immune response comprising contacting immune cells with an antibody that binds to at least one B& molecule and a Rapamycin compound; treating autoimmune diseases such as Lupus erythematosis |
| 12/27/2001 | US20010055589 Cancer immunotherapy improved by prior radiotherapy |
| 12/27/2001 | US20010055581 Admixture of a colloidal metal and a biologically-active factor; colloidal metal reduces or eliminated toxicity so the factor can have therapeutic effect; vaccines, treating cancer |